S. 822In Committee
Scientific EXPERT Act of 2025
Require the FDA to take part in externally led scientific meetings on rare disease drug development and use them to inform review of new drugs and biologics
Plain-English overview
What this bill does
Require the FDA to take part in externally led scientific meetings on rare disease drug development and use them to inform review of new drugs and biologics
Key points
- Establish permanent steering committee
- Require FDA participation in meetings
- Require meeting outcome summaries
- Direct annual rare disease meetings
Current status
Where it stands
Status
In Committee
Latest action
2025-03-03 — Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Related context
Topics and policy areas
undefinedAdvisory bodiesCongressional oversightDrug safety, medical device, and laboratory regulationGovernment information and archivesHealthMedical researchResearch administration and funding